Shwetal Mehta, Ph.D. (she/her)
@smehtalab
Professor, Barrow Neurological Institute Deputy Director, Ivy Brain Tumor Center
It has been such a pleasure to work with @amyyhong @IvyBrainTumCtr over the last five years! She is our go to person when it comes to any data management questions! Looking forward to many more collaborative years, Amy! 👏🏻💪🏼
For the last five years, Amy has been the backbone of our data management team and a core clinical operations team member, helping us achieve new levels of success and innovation. 🌟 Please help us congratulate Amy on all that she has accomplished and contributed! 🎉
Our PK-triggered Phase 0 hybrid trials require extensive assay development and validation. Today Dr. Karapetyan is presenting two posters from @IvyBrainTumCtr on PK assay validation for EGFR inhibitor BDTX-1535 and mTOR inhibitor, Temsirolimus. #AACR2025
Fantastic session on Hippo signaling in cancer @AACR annual meeting. Exciting talks from Georg Halder, Kun-Liang Guan and William Hahn. The talk on the paradoxical data from YAP knockouts vs TEAD inhibitors was very insightful. #AACR2025
Two posters from @IvyBrainTumCtr were presented at the AACR annual meeting by @AnChiTien and Jocelyn Harmon on our ongoing Phase 0/1 trial for EGFR inhibitor (BDTX-1535) in recurrent GBM patients and Factors influencing participant attrition in Phase 0 hybrid trials. #AACR2025.
Susan Histed presenting first of five posters being presented at the AACR Annual Meeting from @IvyBrainTumCtr. Her work focuses on preclinical drug combination studies in glioma models. #AACR2025
Dr Larry Salzman, a physician and cancer survivor emphasized the importance of accessible clinical trials and cancer research for bringing new treatment options for cancer patients upon receiving the Distinguished Public Service award. #AACR2025
Opening plenary at #AACR25 Dr Pat LaRusso honors Dr Larry Salzman with the Distinguished Public Service Award. Thank you Dr Salzman for your fierce advocacy for medical research for life threatening diseases.
.@YoshieUmemura from @IvyBrainTumCtr presenting our PK/PD data from Phase 0/1 trial of AZD1390 which provides support for a phase 2/3 trial. #sno2024
So honored to get the opportunity to present these data on behalf of our incredible team @IvyBrainTumCtr @BarrowNeuro #SNO2024
Insightful presentation by Dr. @smehtalab on Phase 0/2 trial of abemaciclib + LY3214996 in rGBM, showing relevant drug levels but CNS penetration challenges. Don't miss Dr. @YoshieUmemura's talk on our Phase 0/1b trial of AZD1390 in #GBM tomorrow at #SNO2024! @NeuroOnc
Stop by tonight at @AnChiTien ‘s poster on our Phase 0/1 trial with 4th generation EGFR inhibitor in rGBM patients #SNO2024 @IvyBrainTumCtr @BarrowNeuro
Dr. An-Chi Tien presents compelling results from our Phase 0/1 study of BDTX-1535 in recurrent GBM patients with EGFR alterations at #SNO2024. The poster reveals that BDTX-1535 is well-tolerated, achieves pharmacologically relevant concentrations in non-enhancing tumor tissue,…
Great to hear Douglas Hanahan give the Keynote talk at #SNO2024.
I had a great time attending and presenting at the @CUCancerBio retreat this weekend. Fantastic talks from the students and faculty. Thank you to the organizers for inviting me @morgan_fox_ @EllenBamberg and others. It was great catching up with @cittelly and @mitralabcuamc
🎉 Congratulations to Dr. Nader Sanai, director of the Ivy Center, for being named the 2024 Arizona Bioscience Researcher of the Year! Dr. Sanai will receive this award at the 20th Annual @AZBio Awards on Sept. 18. 📰: loom.ly/Ug6S3PE
So great to have three of @IvyBrainTumCtr researchers be part of this amazing @abta community. @AnChiTien @charutafurey and Artak Tovmasyan 👏🏻🧠
Exciting things are happening at the #ABTANationalConference! 🎉 Our amazing AARN members—leading brain tumor researchers—are here sharing groundbreaking ideas and innovations that bring us closer to finding a cure! 🙌💡🧠 #BrainTumorResearch #MeetHopeHeadOn #CureBrainTumors”
As we celebrate the approval of vorasidenib for treatment of grade II IDH-mutant, I would like to recognize those that developed the original compounds. See pubs.acs.org/doi/10.1021/ac…, science.org/doi/10.1126/sc… and perhaps most importantly pubs.acs.org/doi/full/10.10…. Fantastic job!
Next week, we will send off 38 summer research interns @BarrowNeuro with a research symposium packed with student presentations, posters and a keynote speaker who has been my mentor for 25 years! I could not be more excited to welcome Dr. Huganir @rhuganir to Barrow!
Congratulations @MylanBlomquist and Nhan Tran @MayoClinic for your paper on EGFRvIII- and STAT5-dependent sensitivity to Saracatinib treatment in #GBM mdpi.com/1422-0067/25/1…
So excited to get these data out finally. It has been such a pleasure working with @roelverhaak @Kevin_C_Johnson and team! Key take aways - CDK4/6i treatment results in cell state change that is reproducible in vitro and no brain penetration or PD effect seen for Everolimus
Happy to share results from a new Phase 0 trial led by @IvyBrainTumCtr @NaderSanai @smehtalab and @Kevin_C_Johnson: Single nucleus transcriptomics, PK/PD of combined CDK4/6 and mTOR inhibition in a phase 0/1 trial of recurrent high-grade glioma medrxiv.org/content/10.110…
At the Ivy Center, our dedication is to find a cure for brain cancer. On #WorldBrainTumorDay, we continue to push boundaries in brain tumor research to discover new, more effective therapies. Join us in raising awareness in the fight against brain tumors. 🌏🧠
❗🎉 We received FDA approval to proceed with our Phase 3 clinical trial in partnership w/ @GSK! We're accelerating the Gliofocus Study, a global trial comparing niraparib, a PARP1/2 inhibitor, against TMZ for newly diagnosed MGMT-unmethylated #GBM. 📰: loom.ly/ckeho64
The Ivy Brain Tumor Center at Barrow Neurological Institute announced recently a clinical readout of a Phase 0/2 ‘trigger’ clinical trial of niraparib in patients with newly diagnosed MGMT-unmethylated glioblastoma. Click here to learn more: ecs.page.link/R7doD